CSIC and the University of Las Palmas de Gran Canaria have developed a panel of high affinity nanobodies (Nb) binding to diverse SARS-CoV-2 RBD epitopes of spike protein, and a set of nanobody- derived neutralizing heavy chain antibodies (hcAbs) with therapeutic potential in vivo, as they can protect hACE2-transgenic mice after infection with a lethal dose of SARS-CoV-2.
Industrial partners from biotech pharmaceutical industry are being sought to collaborate through a patent licence or co-development agreement
An offer for Patent Licensing or co-development
Material de descarga
More information here